Follow
Ai Li
Ai Li
Director, QED Theraputics
Verified email at qedtx.com
Title
Cited by
Cited by
Year
Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ...
Journal of clinical oncology 33 (25), 2780-2788, 2015
27542015
Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ...
Journal of Clinical Oncology 34 (22), 2619-2626, 2016
5662016
Weighted gene coexpression network analysis: state of the art
W Zhao, P Langfelder, T Fuller, J Dong, A Li, S Hovarth
Journal of biopharmaceutical statistics 20 (2), 281-300, 2010
3872010
Network neighborhood analysis with the multi-node topological overlap measure
A Li, S Horvath
Bioinformatics 23 (2), 222-231, 2007
2352007
Aromatase expression predicts survival in women with early-stage non–small cell lung cancer
V Mah, DB Seligson, A Li, DC Márquez, II Wistuba, Y Elshimali, ...
Cancer research 67 (21), 10484-10490, 2007
1702007
Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score
JS Lam, DB Seligson, H Yu, A Li, M Eeva, AJ Pantuck, G Zeng, S Horvath, ...
BJU international 98 (2), 445-451, 2006
1042006
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants
OQP Yin, N Gallagher, A Li, W Zhou, R Harrell, H Schran
The Journal of Clinical Pharmacology 50 (2), 188-194, 2010
992010
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected …
HK Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R ...
Journal of Clinical Oncology 32 (5s), suppl; abstr 9029, 2014
982014
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating …
HL Kaufman, RHI Andtbacka, FA Collichio, T Amatruda, NN Senzer, ...
Journal of Clinical Oncology 32 (15_suppl), 9008a-9008a, 2014
642014
A group sequential Holm procedure with multiple primary endpoints
Y Ye, A Li, L Liu, B Yao
Statistics in medicine 32 (7), 1112-1124, 2013
612013
Network module detection: affinity search technique with the multi-node topological overlap measure
A Li, S Horvath
BMC research notes 2, 1-14, 2009
552009
Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB …
I Puzanov, MM Milhem, RHI Andtbacka, DR Minor, O Hamid, A Li, J Chou, ...
Journal of Clinical Oncology 33 (15_suppl), 9063-9063, 2015
492015
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV …
RHI Andtbacka, FA Collichio, T Amatruda, N Senzer, J Chesney, ...
Journal for ImmunoTherapy of Cancer 2, 1-2, 2014
322014
Elevated MED28 expression predicts poor outcome in women with breast cancer
NK Yoon, EL Maresh, Y Elshimali, A Li, S Horvath, DB Seligson, D Chia, ...
BMC cancer 10, 1-9, 2010
312010
Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for …
RHI Andtbacka, M Chastain, A Li, M Shilkrut, MI Ross
Journal of Clinical Oncology 33 (15_suppl), TPS9094-TPS9094, 2015
242015
Higher expression levels of 14-3-3σ in ductal carcinoma in situ of the breast predict poorer outcome
NK Yoon, DB Seligson, D Chia, Y Elshimali, G Sulur, A Li, S Horvath, ...
Cancer Biomarkers 5 (4-5), 215-224, 2009
202009
Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma
JJ Nemunaitis, RH Andtbacka, M Ross, T Amatruda, J Chesney, ...
Annals of Oncology 25, iv382, 2014
92014
Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in …
I Puzanov, M Milhem, R Andtbacka, D Minor, O Hamid, A Li, ...
Journal for ImmunoTherapy of Cancer 1, 1-2, 2013
92013
Efficacy and safety of ATA129, partially matched allogeneic third-party Epstein-Barr virus-targeted cytotoxic T lymphocytes in a multicenter study for post-transplant …
S Prockop, A Li, RA Baiocchi, N Bunin, KM Mahadeo, ER Nemecek, ...
Blood 130, 4520, 2017
72017
Tissue microarrays: construction and utilization for biomarker studies
SM Mumenthaler, N Yoon, A Li, V Mah, G Chang, F Nooraie, Y Elshimali, ...
Methods of Cancer Diagnosis, Therapy and Prognosis: Breast Carcinoma, 217-234, 2008
32008
The system can't perform the operation now. Try again later.
Articles 1–20